INTRODUCTION {#s1}
============

According to the latest cancer statistics, lung cancer is one of the malignant tumors with the highest morbidity and mortality all over the world \[[@R1]--[@R3]\]. Approximate 14.1 million new cancer cases occurred in 2012, including about 1.8 million lung cancer cases, which constituted about 12.8% of all new cancer cases \[[@R3]\]. As we all know, the leading risk factor for lung cancer is smoking \[[@R4]\]. However, more and more studies indicate that genetic risk factors may also play an important part in the occurrence and development of lung cancer \[[@R5]--[@R7]\]. Meanwhile, the interaction between genes and smoking may exist. Therefore, this study intended to explore the association between single nucleotide polymorphisms (SNPs) and the susceptibility of lung cancer, and the interaction between SNPs and smoking on lung cancer risk.

MIR217HG (MIR217 host gene) is located in 2p16. It is the host gene of MIR217. Some previous studies demonstrate that MIR217 is closely related to the occurrence and development of tumor. For example, N. A. Schultz et al \[[@R8]\] proved the diagnostic MIR217 expression profile associated with pancreatic cancer, which was described by Szafranska et al \[[@R9]\]. However, up to now, there are no reports about the function of MIR217HG and the association between MIR217HG and any diseases.

The Gab-family adapter proteins are also known as the Grb2-associated binder family adapter proteins, which are scaffolding adapter molecules \[[@R10]\]. Gab proteins mainly consist of Gab1, Gab2 and Gab3 \[[@R11]\]. The weights of Gab1 molecules are 100-120KD \[[@R12], [@R13]\]. Gab1 is located in 4q31 and it most mainly exists in brain, kidney, lung, heart, testis, and ovary \[[@R13], [@R14]\]. According to previous studies \[[@R13], [@R15]\], Gab1 worked in EGF receptor / ErbB-mediated cell transformation, which indicated that Gab1 played an important role in oncogenic signaling pathways. Fan Y et al \[[@R16]\] found that Gab1 had the overexpression in chondrosarcoma tissues, which made Gab1 be considered as a novel biomarker of diagnosis and prognosis of chondrosarcoma. The study of Bai R et al \[[@R17]\] indicated that Gab1 played a role in the function exertion of miR-409-3p, which was considered as a metastatic suppressor. However, to the best of my knowledge, no study about the association between Gab1 and lung cancer was carried out.

Given that the relationship between MIR217HG, Gab1 and lung cancer was undefined, the present study evaluated the relationship between MIR217HG-rs1347093, Gab1-rs1397529 polymorphisms and lung cancer susceptibility and investigated the interaction between MIR217HG-rs1347093, Gab1-rs1397529 polymorphisms and smoking status on the risk of lung cancer, which could provide a new strategy of lung cancer screening in Chinese population.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

The demographic characteristics of 825 cases and 766 controls were shown in Table [1](#T1){ref-type="table"}. In case group, there were 483 cases of adenocarcinoma, 207 cases of squamous cell carcinoma, 95 cases of small cell lung cancer and 40 cases of other histological type. There was no significant difference in the distribution of age (*P* = 0.197) between lung cancer patients and controls with the mean age for cases and controls were 58.567 ± 11.054 and 57.158 ± 13.341 respectively. However, there was a significant difference in the distributions of gender and smoking (both were *P\<*0.001). Therefore, the further study was adjusted by gender, age and smoking.

###### Demographics of the study subjects

  Characteristics                Cases n(%)      Controls n(%)   *P*
  ------------------------------ --------------- --------------- ---------
  Gender                                                         \<0.001
  Female                         619(75.0)       658(85.9)       
  Male                           206(25.0)       108(14.1)       
  Age (years)                    58.567±11.054   57.158±13.341   0.197
  Stage^\*^                                                      
  I                              52(7.8)                         
  II                             132(19.9)                       
  III                            331(49.9)                       
  IV                             149(22.4)                       
  Histological type                                              
  Adenocarcinoma                 483(58.5)                       
  Squamous cell carcinoma        207(25.1)                       
  Small cell lung cancer         95(11.5)                        
  other                          40(4.9)                         
  Family history of cancer^\*^                                   0.912
  yes                            68(12.6)        82(12.8)        
  no                             471(87.4)       557(87.2)       
  Smoking                                                        \<0.001
  yes                            183(22.2)       54(7.0)         
  no                             642(77.8)       712(93.0)       

^\*^There are missing values.

The distributions of genotypes, alleles and associations with lung cancer {#s2_2}
-------------------------------------------------------------------------

Distributions of rs1347093, rs1397529 genotypes and alleles among subjects and their associations with the risk of lung cancer were summarized in Table [2](#T2){ref-type="table"}. The observed genotype frequencies of rs1347093, rs1397529 among controls was in agreement with Hardy-Weinberg equilibrium (χ^2^ = 0.984, *P =* 0.321 for rs1347093; χ^2^ = 0.154, *P =* 0.695 for rs1397529). For the distribution of rs1347093, A allele had the relationship with a significantly reduced risk of lung cancer (adjusted OR = 0.619, 95%CI = 0.436-0.877, *P=*0.007), compared with C allele. Meanwhile, AC genotype of the rs1347093 was linked to reduced risk of lung cancer compared to CC genotype (AC vs. CC: adjusted OR = 0.594, 95%CI = 0.413-0.853, *P=*0.005). Besides, we observed that a significant association between the rs1347093 polymorphism and reduced risk of lung cancer existed in a dominant genetic model, assuming that the variant genotypes (AC+AA) was the dominant genetic model (AC+AA vs. CC: adjusted OR = 0.599, 95%CI = 0.418-0.858, *P=*0.005). For the distribution of rs1397529, C allele had the relationship with a significantly reduced risk of lung cancer (adjusted OR = 0.697, 95%CI = 0.526-0.926, *P=*0.013), compared with A allele. Meanwhile, a significant association between the rs1397529 polymorphism and reduced risk of lung cancer in one genetic model could be observed (AC vs. AA: adjusted OR = 0.649, 95%CI = 0.476-0.884, *P=*0.006). Besides, we observed that a significant association between the rs1397529 polymorphism and reduced risk of lung cancer existed in a dominant genetic model, assuming that the variant genotypes (AC+CC) was the dominant genetic model (AC+CC vs. AA: adjusted OR = 0.664, 95%CI = 0.491-0.897, *P=*0.008).

###### Distributions of rs1347093, rs1397529 genotypes and alleles among lung cancer cases and controls and their associations with the risk of lung cancer

  Genotype    Cases n(%)   Controls n(%)   *P*     OR \[[@R5]\]          *P* adj   OR\[95%CI\] adj
  ----------- ------------ --------------- ------- --------------------- --------- ---------------------
  rs1347093                                                                        
  CC          768(93.1)    680(88.8)               1.00(ref)                       1.00(ref)
  AC          56(6.8)      85(11.1)        0.003   0.583(0.410,0.830)    0.005     0.594(0.413,0.853)
  AA          1(0.1)       1(0.1)          0.931   0.885(0.055,14.183)   0.978     1.040(0.065,16.667)
  AC/AA       57(6.9)      86(11.2)        0.003   0.587(0.413,0.833)    0.005     0.599(0.418,0.858)
  C           1592(96.5)   1445(94.3)              1.00(ref)                       1.00(ref)
  A           58(3.5)      87(5.7)         0.004   0.605(0.431,0.850)    0.007     0.619(0.436,0.877)
  rs1397529                                                                        
  AA          736(89.2)    646(84.3)               1.00(ref)                       1.00(ref)
  AC          83(10.1)     114(14.9)       0.004   0.639(0.473,0.864)    0.006     0.649(0.476,0.884)
  CC          6(0.7)       6(0.8)          0.822   0.878(0.282,2.735)    0.944     0.959(0.303,3.039)
  AC/CC       89(10.8)     120(15.7)       0.004   0.651(0.485,0.873)    0.008     0.664(0.491,0.897)
  A           1555(94.2)   1406(91.8)              1.00(ref)                       1.00(ref)
  C           95(5.8)      126(8.2)        0.006   0.682(0.517,0.898)    0.013     0.697(0.526,0.926)

*P* adj and OR\[95%CI\] adj were adjusted for age, gender and smoking.

Stratification analyses {#s2_3}
-----------------------

In order to further study the relationship between rs1347093, rs1397529 polymorphism and lung cancer risk, we conducted several stratification analyses in the dominant genetic model. As shown in Table [3](#T3){ref-type="table"}, AA/AC genotype of rs1347093 had the relationship with a significantly decreased risk of lung cancer in adenocarcinoma subgroup (adjusted OR = 0.598, 95%CI = 0.393-0.912, *P=*0.017) and small cell lung cancer subgroup (adjusted OR = 0.296, 95%CI = 0.106-0.826, *P=*0.020), compared with CC genotype. There was no significant association between the dominant genetic model of rs1347093 and the susceptibility of lung cancer in squamous cell carcinoma subgroup. For rs1397529, CC/AC genotype was linked with a significantly decreased risk of lung cancer in adenocarcinoma subgroup (adjusted OR = 0.689, 95%CI = 0.488-0.974, *P=*0.035), compared with AA genotype. We failed to observe a significant association between the dominant genetic model of rs1397529 and the susceptibility of lung cancer in squamous cell carcinoma subgroup and small cell lung cancer subgroup.

###### The effect of the SNPs rs1347093 and rs1397529 in the region on lung cancer risk in pathological subgroup

  Genotype                  Cases n(%)   Controls n(%)   *P* value   OR(95%CI)            *P* adj   OR(95%CI) adj
  ------------------------- ------------ --------------- ----------- -------------------- --------- --------------------
  rs1347093                                                                                         
  Adenocarcinomas                                                                                   
  CC                        450(93.2)    680(88.8)                   1.00(ref)                      1.00(ref)
  AA/AC                     33(6.8)      86(11.2)        0.011       0.580(0.382,0.881)   0.017     0.598(0.393,0.912)
  Squamous cell carcinoma                                                                           
  CC                        188(90.8)    680(88.8)                   1.00(ref)                      1.00(ref)
  AA/AC                     19(9.2)      86(11.2)        0.400       0.799(0.474,1.347)   0.522     0.826(0.460,1.484)
  Small cell lung cancer                                                                            
  CC                        91(95.8)     680(88.8)                   1.00(ref)                      1.00(ref)
  AA/AC                     4(4.2)       86(11.2)        0.015       0.280(0.101,0.778)   0.020     0.296(0.106,0.826)
  rs1397529                                                                                         
  Adenocarcinomas                                                                                   
  AA                        429(88.8)    646(84.3)                   1.00(ref)                      1.00(ref)
  AC/CC                     54(11.2)     120(15.7)       0.026       0.678(0.481,0.955)   0.035     0.689(0.488,0.974)
  Squamous cell carcinoma                                                                           
  AA                        186(89.9)    646(84.3)                   1.00(ref)                      1.00(ref)
  AC/CC                     21(10.1)     120(15.7)       0.047       0.608(0.372,0.994)   0.171     0.686(0.401,1.176)
  Small cell lung cancer                                                                            
  AA                        87(91.6)     646(84.3)                   1.00(ref)                      1.00(ref)
  AC/CC                     8(8.4)       120(15.7)       0.066       0.495(0.234,1.048)   0.084     0.515(0.242,1.093)

*P* adj and OR\[95%CI\] adj were adjusted for age, gender and smoking.

Table [4](#T4){ref-type="table"} summarized the associations between rs1347093, rs1397529 polymorphism and lung cancer risk, stratified by clinical stages. We could obtain a significant association between AA/AC genotype of rs1347093 and reduced risk of lung cancer in comparison with CC genotype in stage III+ IV subgroup (adjusted OR = 0.568, 95%CI = 0.368-0.876, *P=*0.011). Meanwhile, we also observed that CC/AC genotype of rs1397529 was associated with reduced risk of lung cancer in comparison with AA genotype in stage III+ IV subgroup (adjusted OR = 0.647, 95%CI = 0.452-0.925, *P=*0.017).

###### Associations between rs134709, rs1397529 polymorphisms and lung cancer susceptibility, stratified by stages

  Genotype        Cases n(%)   Controls n(%)   *P*     OR(95%CI)            *P adj*   OR(95%CI) adj
  --------------- ------------ --------------- ------- -------------------- --------- --------------------
  rs1347093                                                                           
  stage I+II                                                                          
  CC              169(91.8)    680(88.8)               1(ref)                         1(ref)
  AA/AC           15(8.2)      86(11.2)        0.226   0.702(0.395,1.246)   0.232     0.700(0.390,1.256)
  stage III+ IV                                                                       
  CC              449(93.5)    680(88.8)               1(ref)                         1(ref)
  AA/AC           31(6.5)      86(11.2)        0.006   0.546(0.356,0.837)   0.011     0.568(0.368,0.876)
  rs1397529                                                                           
  stage I+II                                                                          
  AA              165(89.7)    646(84.3)               1(ref)                         1(ref)
  AC/CC           19(10.3)     120(15.7)       0.068   0.620(0.371,1.036)   0.111     0.655(0.390,1.102)
  stage III+ IV                                                                       
  AA              431(89.8)    646(84.3)               1(ref)                         1(ref)
  AC/CC           49(10.2)     120(15.7)       0.007   0.612(0.430,0.872)   0.017     0.647(0.452,0.925)

*P* adj and OR\[95%CI\] adj were adjusted for age, gender and smoking.

Table [5](#T5){ref-type="table"} showed the associations between rs1347093, rs1397529 polymorphism and lung cancer risk, stratified by smoking. We observed a significant association between AA/AC genotype of rs1347093 and reduced risk of lung cancer in both smoking subgroup and non-smoking subgroup, compared with CC genotype (smoking subgroup: adjusted OR = 0.664, 95%CI = 0.491-0.897, *P=*0.008; non-smoking subgroup: adjusted OR = 0.559, 95%CI = 0.380-0.823, *P=*0.003). We also observed that CC/AC genotype of rs1397529 was linked to reduced risk of lung cancer in non-smoking subgroup, compared with AA genotype (adjusted OR = 0.595, 95%CI = 0.430-0.822, *P=*0.002).

###### Associations between rs1347093, rs1397529 polymorphisms and lung cancer susceptibility, stratified by smoking status

  Genotypes     Cases n(%)   Controls n(%)   *P*     OR\[95%CI\]          *P* adj   OR\[95%CI\] adj
  ------------- ------------ --------------- ------- -------------------- --------- --------------------
  rs1347093                                                                         
  Non-exposed                                                                       
  CC            599(93.3)    630(88.5)               1(ref)                         1(ref)
  AC/AA         43(6.7)      82(11.5)        0.002   0.552(0.375,0.811)   0.003     0.559(0.380,0.823)
  Exposed                                                                           
  CC            169(92.3)    50(92.6)                1(ref)                         1(ref)
  AC/AA         14(7.7)      4(7.4)          0.004   0.651(0.485,0.873)   0.008     0.664(0.491,0.897)
  rs1397529                                                                         
  Non-exposed                                                                       
  AA            576(89.7)    596(83.7)               1(ref)                         1(ref)
  AC/CC         66(10.3)     116(16.3)       0.001   0.589(0.426,0.813)   0.002     0.595(0.430,0.822)
  Exposed                                                                           
  AA            160(87.4)    50(92.6)                1(ref)                         1(ref)
  AC/CC         23(12.6)     4(7.4)          0.300   1.797(0.593,5.443)   0.301     1.800(0.591,5.478)

*P* adj and OR\[95%CI\] adj were adjusted for age and gender.

Table [6](#T6){ref-type="table"} listed the associations between rs1347093, rs1397529 polymorphism and lung cancer risk, stratified by gender. We observed a significant association between AA/AC genotype of rs1347093 and reduced risk of lung cancer in comparison with CC genotype in the female subgroup (adjusted OR = 0.582, 95%CI = 0.391-0.866, *P=*0.008). We also found that CC/AC genotype of rs1397529 was associated with reduced risk of lung cancer in comparison with AA genotype in the female subgroup (adjusted OR = 0.605, 95%CI = 0.432-0.847, *P=*0.003).

###### Associations between rs1347093, rs1397529 polymorphisms and lung cancer susceptibility, stratified by gender

  Genotypes   Cases n(%)   Controls n(%)   *P*     OR\[95%CI\]          *P* adj   OR\[95%CI\] adj
  ----------- ------------ --------------- ------- -------------------- --------- --------------------
  rs1347093                                                                       
  Female                                                                          
  CC          576(93.1)    584(88.8)               1(ref)                         1(ref)
  AC/AA       43(6.9)      74(11.2)        0.008   0.589(0.398,0.873)   0.008     0.582(0.391,0.866)
  Male                                                                            
  CC          192(93.2)    96(88.9)                1(ref)                         1(ref)
  AC/AA       14(6.8)      12(11.1)        0.192   0.583(0.260,1.310)   0.360     0.665(0.278,1.592)
  rs1397529                                                                       
  Female                                                                          
  AA          556(89.8)    555(84.3)               1(ref)                         1(ref)
  AC/CC       63(10.2)     103(15.7)       0.004   0.611(0.437,0.853)   0.003     0.605(0.432,0.847)
  Male                                                                            
  AA          180(87.4)    91(84.3)                1(ref)                         1(ref)
  AC/CC       26(12.6)     17(15.7)        0.446   0.773(0.399,1.498)   0.993     0.997(0.486,2.045)

*P* adj and OR\[95%CI\] adj were adjusted for age and smoking.

Interaction between rs1347093, rs1397529 and smoking {#s2_4}
----------------------------------------------------

The results of crossover analysis were listed in Tables [7](#T7){ref-type="table"} and [8](#T8){ref-type="table"}. We could find that there was no significant interaction between rs1347093, rs1397529 and smoking on lung cancer risk. The logistic regression model also demonstrated that interaction didn't exist between rs1347093, rs1397529 and smoking on risk of lung cancer (Table [9](#T9){ref-type="table"}).

###### Interaction between rs1347093, rs1397529 polymorphisms and smoking on lung cancer susceptibility

  SNP         Smoking        Cases   Controls   *P*       OR(95%CI)              *P* adj   OR(95%CI) adj
  ----------- -------------- ------- ---------- --------- ---------------------- --------- ----------------------
  rs1347093                                                                                
  AA/AC       Non-exposure   43      82                   1(ref)                           1(ref)
  CC          Non-exposure   599     630        0.002     1.813(1.233,2.666)     0.003     1.785(1.212,2.628)
  AA/AC       Exposure       14      4          0.001     6.674(2.070,21.524)    \<0.001   9.202(2.704,31.318)
  CC          Exposure       169     50         \<0.001   6.446(3.966,10.474)    \<0.001   9.007(4.877,16.637)
  rs1397529                                                                                
  CC/AC       Non-exposure   66      116                  1(ref)                           1(ref)
  AA          Non-exposure   576     596        0.001     1.699(1.230,2.347)     0.002     1.679(1.215,2.322)
  CC/AC       Exposure       23      4          \<0.001   10.106(3.351,30.480)   \<0.001   13.885(4.344,44.385)
  AA          Exposure       160     50         \<0.001   5.624(3.628,8.718)     \<0.001   7.723(4.364,13.668)

*P* adj and OR\[95%CI\] adj were adjusted for age and gender.

###### Crossover analysis of interaction between rs1347093, rs1397529 polymorphisms and smoking on lung cancer susceptibility

  Measure     Estimate   Lower     Upper
  ----------- ---------- --------- -------
  rs1347093                        
  RERI        -0.975     -11.307   9.356
  AP          -0.108     -1.255    1.038
  S           0.891      0.282     2.814
  rs1397529                        
  RERI        -6.845     -15.522   1.832
  AP          -0.886     -2.899    1.126
  S           0.495      0.146     1.686

###### Logistic model of interaction between rs1347093, rs1397529 polymorphisms and smoking on lung cancer susceptibility

  Variables     Cases   Controls   *P adj*   OR(95%CI) adj
  ------------- ------- ---------- --------- ----------------------
  rs1347093                                  
  SNP                                        
  AC/AA         57      86                   1(ref)
  CC            768     680        0.003     1.785(1.212,2.628)
  smoking                                    
  no            471     557                  1(ref)
  yes           68      82         \<0.001   9.202(2.704,31.318)
  interaction                      0.334     0.548(0.162,1.857)
  rs1397529                                  
  SNP                                        
  AC/CC         89      120                  1(ref)
  AA            736     646        0.002     1.679(1.215,2.322)
  smoking                                    
  no            471     557                  1(ref)
  yes           68      82         \<0.001   13.885(4.344,44.385)
  interaction                      0.061     0.331(0.104,1.052)

*P* adj and OR\[95%CI\] adj were adjusted for age and gender.

DISCUSSION {#s3}
==========

In recent years, more and more studies about the association between SNPs and lung cancer risk were conducted. The studies of Chen D \[[@R18]\], Xie K \[[@R19]\], Yin Z \[[@R20]\] et al all came to a significant conclusion. SNPs play an important role in the occurrence, development and prognosis of lung cancer \[[@R21]\]. In the present study, we evaluated the association between rs1347093, rs1397529 polymorphisms and lung cancer susceptibility by the statistical method in 825 cases and 766 controls. The results of the study indicated that rs1347093, rs1397529 polymorphisms were associated with lung cancer risk, especially with adenocarcinoma risk. For rs1347093 in MIR217HG, the individuals who carry the dominant genetic model (AC+AA) have less risk of lung cancer than those who carry CC genotype. For rs1397529 in Gab1, the individuals who carry the dominant genetic model (AC+CC) have less risk of lung cancer than those who carry AA genotype. In stratification analyses by histological type, we found that the individuals who carry the dominant genetic model of rs1347093, rs1397529 have less risk of adenocarcinoma, compared with those individuals who don't carry the dominant genetic model of rs1347093, rs1397529. For rs1347093, the similar result was found in small cell lung cancer subgroup. The individuals who carry the dominant genetic model (AC+CC) have less risk of small cell lung cancer than those who carry AA genotype. The stratification analysis showed that the association of rs1347093, rs1397529 to risk of lung cancer was mainly derived from female. This may be on account of differences of men and women in the physiological and genetic aspects. We will research this issue further in the later study. We also researched interaction between rs1347093, rs1397529 and smoking on lung cancer risk. However, the results indicated that the interaction didn't exist. One of the reasons may be that the number of subjects with the exposure of tobacco is not large enough to get a statistically significant difference.

rs1347093 is located in the intron region of MIR217HG, and rs1397529 is located in the UTR-3 region of Gab1. Although they can't code proteins, they might have regulating effects, which might have an effect on gene function. Thus rs1347093, rs1397529 polymorphisms might influence the function of genes and might have the relationship with diseases. The function of rs1347093 and rs1397529 will be studied in our future study. Gab1 is a docking protein, which can transduce signals from all various tyrosine kinases \[[@R22]\]. Expression of Gab1 is associated with many cancer, such as ovarian cancer \[[@R23]\], breast cancer \[[@R22]\], chondrosarcoma \[[@R16]\], colorectal cancer \[[@R17]\], urothelial cell carcinoma \[[@R24]\] and so on. MIR217HG is the host gene of MIR217. Although the function of MIR217HG was undefined, there were multiple studies about function of MIR217 in different types of tumors. The studies of Su J, Wang H, Zhou W, Li H, Shen L, Guo J, Zhu Y, Wang X, Li J, N. A. Schultz et al respectively linked MIR217 to hepatocellular carcinoma \[[@R25]\], gastric Cancer \[[@R26]\], breast cancer \[[@R27]\], renal cell carcinoma \[[@R28]\], osteosarcoma \[[@R29]\], lung cancer \[[@R30]\], glioma \[[@R31]\], esophageal carcinoma \[[@R32]\], ovarian cancer \[[@R33]\], pancreatic cancer \[[@R8]\] et al.

In our research, the newly-diagnosed patients were selected as cases, which could effectively avoid the Neyman bias. Given that the prevalent patients are more likely to change the exposure status of environmental factors and living habits, compared with the newly-diagnosed patients, which is beneficial to survive with lung cancer, the prevalent patients shouldn't be selected as the studying subjects. The cases and controls were selected from the same hospital, which could effectively avoid the Berkson bias. The observed genotype frequencies of rs1347093, rs1397529 among controls was in agreement with Hardy-Weinberg equilibrium, which means our studying subjects have good representativeness. In the present study, we carried out our studies, adjusting by gender, age and smoking. Above all of these could effectively improve the reliability of the results.

Our study firstly find that rs1347093, rs1397529 polymorphisms are associated with lung cancer risk in northeast Chinese population. However, some limitations should be considered before drawing a conclusion. Firstly, the present study is a hospital-based study, in which subjects in the control group are from the medical examination centers of the hospitals where our cases are selected. Therefore, controls may not be representative for the whole Chinese population very well. Secondly, in this study, all the subjects are from northeast China, thus a more diversified population should be selected to prove this results in the future study.

MATERIALS AND METHODS {#s4}
=====================

Subject data collection {#s4_1}
-----------------------

We carried out the hospital-based case-control study in Shenyang city which is located in the northeast China. Our study subjects consisted of 825 cases and 766 controls. All cases were diagnosed newly as lung cancer by the professional pathologists between March 2010 and January 2014. At the same time, we randomly selected people without a history of cancer as controls in the same hospital. In addition, we defined environmental exposure on the basis of our previous study \[[@R34]\]. Subjects who smoke more than 100 cigarettes in their lifetime were defined as smokers. Cases and controls were all unrelated ethic Han-Chinese people who lived in northeast and they had signed informed consent forms.

DNA genotyping {#s4_2}
--------------

Firstly, we obtained a 5ml venous blood samples from every participant and isolated genomic DNA by phenol-chloroform method. A 7500 Fast Real-time PCR system (Applied Biosystems, Foster City, CA, USA) performed SNP genotyping to design PCR Taqman primers and probes (assay ID C\_\_\_2076188_10 for rs1347093 and C\_\_\_289707_10 for rs1397529), using Applied Biosystems (CA, USA). The reaction conditions of the quantitative real-time PCR (q PCR) was as follows: 10min at 95°C following by 47 cycles of 92°C for 30s and 1min at 60°C. An ABI 7500 FAST Real-Time PCR System read the results of reaction, using the Sequence Detection Software. For the sake of quality control, the researchers were blinded to grouping state of subjects and we randomly selected 10% samples to carry out genotyping a second time. The results of the duplicated genotyping were 100% consistent with the former ones.

Statistical analysis {#s4_3}
--------------------

T test and χ^2^ test were carried out to examine the difference of demographic variables and smoking status between cases and controls. Hardy-Weinberg equilibrium (HWE) was examined by a goodness-of-fit χ^2^ test in the control group. The odds ratios (OR) and 95% confident intervals (95% CI) were calculated by unconditional logistic regression analysis to estimate the relationship between SNP and the susceptibility of lung cancer. Multiplicative model and addictive model were conducted to evaluate the interaction between gene polymorphism and smoking status on lung cancer susceptibility. In multiplicative model, The odds ratios (OR) and 95% confident intervals (95%CI) were calculated in the logistic regression model to estimate the interaction. In addictive model, RERI (Relative Excess Risk due to Interaction), AP (Attributable Proportion due to Interaction), and S (Synergy Index) was used to estimate the interaction. When the 95%CI of S didn't include 1 and the 95%CI of RERI and AP didn't include 0, there was statistically significant interaction \[[@R35]\]. Almost analyses were adjusted by age, gender and smoking. All above analyses were two-sided, and were carried out by SPSS software (vision 20.0) unless specified. The criterion of statistical significance was defined as P\<0.05.

CONCLUSIONS {#s5}
===========

The results of the present study demonstrate that significant association between rs1347093, rs1397529 polymorphism and susceptibility to lung cancer may exist in northeast Chinese population. There is no significant interaction between rs1347093, rs1397529 polymorphism and smoking on susceptibility of lung cancer.
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